Robert Langreth
Science and Health Reporter-at-Large at Bloomberg News
Science and health reporter at large, Bloomberg News
Articles
-
3 weeks ago |
news.bloombergtax.com | Robert Langreth |Gerry Smith
Susan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headachesif she tried a new drug from Eisai Co. that promised to slow the progression of her disease. It didn’t sound like a dealbreaker, so she decided to try it. Two weeks after her third dose, Aaron was dead.
-
3 weeks ago |
news.bloomberglaw.com | Robert Langreth |Gerry Smith
Susan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headachesif she tried a new drug from Eisai Co. that promised to slow the progression of her disease. It didn’t sound like a dealbreaker, so she decided to try it. Two weeks after her third dose, Aaron was dead.
-
3 weeks ago |
bostonglobe.com | Robert Langreth |Gerry Smith
“They should have known not to take her with her genetic status,” Porter said in an interview. “It’s almost like they put her in front of a firing squad.”Valerie Porter.Laurel Golio/Photographer: Laurel GolioThe hospital declined to comment on Aaron’s case, citing confidentiality laws, but said all patients with genetic risk factors are warned of these risks.
-
3 weeks ago |
nationalpost.com | Robert Langreth |Gerry Smith
Three others also suffered lasting disabilities, according to FDA reports obtained by a Freedom of Information Act request • You can save this article by registering for free here. Or sign-in if you have an account. Article contentSusan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headaches if she tried a new drug from Eisai Co. that promised to slow the progression of her disease.
-
3 weeks ago |
bloomberg.com | Robert Langreth |Gerry Smith
Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world For Customers Bloomberg Anywhere Remote Login Software Updates Manage Products and Account Information Support Americas+1 212 318 2000 EMEA+44 20 7330 7500 Asia Pacific+65 6212 1000 Company About Careers Inclusion at Bloomberg Tech at Bloomberg Philanthropy Sustainability Bloomberg London...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 7K
- Tweets
- 747
- DMs Open
- No
RT @SamHornblower: Alzheimer’s research has been stuck for decades—but is flawed science and research integrity part of the problem? Today…
RT @nncattan: If it works, “we will price it at a level that will democratize weight loss,” he said in an interview at Bloomberg headquarte…
RT @nncattan: AstraZeneca's Chief Executive Officer Pascal Soriot envisions his company bringing more affordable drugs to people who need t…